Citius Oncology Inc (CTOR)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-05
$0.50-8.57%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-05
QuarterlyIQ Insights · CTOR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
“We are now more than halfway to our goal of having LYMPHIR on formulary at 100 priority institutions by calendar year-end.
Stated in 2 of 2 supplied quarters. Management reported: “Exhibit 99.1 Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026 CRANFORD, N.J., October 26, 2026 - Citius Oncology, Inc. (“Citius Oncology” or the “Company”) (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR), today announced preliminary, unaudited LYMPHIR ® (denileukin diftitox-cxdl) unit sales to U.S. wholesalers and institutional vial orders for the fiscal fourth quarter ended September 30, 2026.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Citius Oncology is now well positioned to broaden engagement with treatment centers, targeting formulary inclusion at 100 priority institutions by year-end and first-in-class support for health care…”
“We have achieved strong institutional penetration for a newly launched specialty therapy, with 83% of our target accounts having added LYMPHIR or actively progressing it through formulary review.”
In August, our full 29-person-strong commercial and medical affairs organizations expanded to nationwide coverage.
Stated in 2 of 2 supplied quarters. Management reported: “In August, our full 29-person-strong commercial and medical affairs organizations expanded to nationwide coverage.” “We expect to have the full commercial team deployed by mid-summer.”
“In August, our full 29-person-strong commercial and medical affairs organizations expanded to nationwide coverage.”
“We expect to have the full commercial team deployed by mid-summer.”
At the same time, we continue to advance LYMPHIR’s longer-term value proposition through investigator-initiated studies exploring its potential in combination regimens beyond CTCL,” added Mazur.
Stated in 2 of 2 supplied quarters. Management reported: “At the same time, we continue to advance LYMPHIR’s longer-term value proposition through investigator-initiated studies exploring its potential in combination regimens beyond CTCL,” added Mazur.” “Together, these execution milestones and data-driven catalysts reinforce our view that LYMPHIR can be developed beyond U.S. CTCL as a platform asset in combination regimens.”
“At the same time, we continue to advance LYMPHIR’s longer-term value proposition through investigator-initiated studies exploring its potential in combination regimens beyond CTCL,” added Mazur.”
“Together, these execution milestones and data-driven catalysts reinforce our view that LYMPHIR can be developed beyond U.S. CTCL as a platform asset in combination regimens.”
Expand institutional adoption, formulary inclusion, and wholesaler sales for LYMPHIR in the U.S. CTCL market.
Deploy commercial and medical affairs teams nationwide to increase treatment-center engagement and support broader adoption.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
15 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.